{"entity":{"id":"nct03851640","kind":"trial","name":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","aka":[],"tldr":"A phase 3 trial of HC-1119 in prostate cancer, run by Hinova Pharmaceuticals Inc., now recruiting.","summary":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). is a phase 3 interventional study registered as NCT03851640 by Hinova Pharmaceuticals Inc., with 417 participants planned, started 2019-04-12 and due to reach its primary completion in 2025-09. Interventions recorded: HC-1119 and placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03851640","url":"https://clinicaltrials.gov/study/NCT03851640"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hinova-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct03851640-signal-transduct-target-ther-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03851640","phase":"3","setting":"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Failed Treatments with Abiraterone Acetate and Docetaxel.","sponsor":"Hinova Pharmaceuticals Inc.","participation":[{"nct":"NCT03851640","source":"https://clinicaltrials.gov/study/NCT03851640","fetchedAt":"2026-10-07T16:53:10.205Z","studySha256":"491e1600dac66eaf8d1aaf39ae799bd9ab3cbdc782f4605e6626e61757d36113","overallStatus":"RECRUITING","lastUpdatePosted":"2025-03-12","leadSponsor":"Hinova Pharmaceuticals Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":417,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2019-04-12","startedType":"actual","enrolled":417,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03851640/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/"}],"paper":[{"id":"paper-nct03851640-signal-transduct-target-ther-2026","kind":"paper","name":"Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial","route":"/key-papers/paper-nct03851640-signal-transduct-target-ther-2026/"}]}}